Crossmark

Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults

Crossref DOI link: https://doi.org/10.1016/j.eimce.2018.04.019

Published Print: 2019-03

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Pérez-Molina, José Antonio

Martínez, Esteban

Blasco, Antonio Javier

Arribas, José Ramón

Domingo, Pere

Iribarren, José Antonio

Knobel, Hernando

Lázaro, Pablo

López-Aldeguer, José

Lozano, Fernando

Mariño, Ana

Miró, José M.

Moreno, Santiago

Negredo, Eugenia

Pulido, Federico

Rubio, Rafael

Santos, Jesús

de la Torre, Javier

Tuset, Montserrat

von Wichmann, Miguel A.

Gatell, Josep M.
License Information

Text and Data Mining valid from 2019-03-01
More Information

This article is maintained by: Elsevier

Article Title: Analysis of the costs and cost-effectiveness of the guidelines recommended by the 2018 GESIDA/Spanish National AIDS Plan for initial antiretroviral therapy in HIV-infected adults

Journal Title: Enfermedades infecciosas y microbiologia clinica (English ed.)

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eimce.2018.04.019

Content Type: article

Copyright: © 2018 Elsevier España, S.L.U. and Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. All rights reserved.

Document is current

Any future updates will be listed below